Pharmaceutical returns are often evaluated by execution: Was the product processed correctly? Was eligible credit recovered? Was the return handled efficiently?
But regulated products remain subject to security, accountability and regulatory requirements through final disposition. The processes, expertise and technology behind the return matter as much as the transaction itself.
When evaluating a pharmaceutical reverse distributor, five capabilities deserve closer consideration.
1. Regulatory Expertise That Extends Beyond the Transaction
A reverse distributor operates at the intersection of federal and state requirements, manufacturer policies, controlled substance regulations, and product-specific disposition requirements.
Healthcare organizations should look for regulatory expertise embedded within the operation and processes that can adapt as requirements evolve.
Compliance is not static. A strong partner should demonstrate how regulatory knowledge informs procedures and governance—and translates changing requirements into clear guidance and practical action.
2. Security and Accountability Throughout the Process
Healthcare organizations should understand the controls surrounding pharmaceutical products after they leave their facilities—from receipt and processing through storage, movement and final disposition. Controlled substances require particularly rigorous safeguards, but security and accountability should be foundational across the operation.
Inmar’s commitment to accountability is exemplified by monthly accountability audits of at least two randomly selected controlled substances that are physically counted to the dosage unit and tracked to show month-over-month trends. Inmar consistently maintains an average variance of less than 1%. Monthly environmental compliance audits are also performed to ensure pharmaceutical waste is managed safely and disposed of according to product characterization.
Organizations should consider how a partner establishes a chain of custody, monitors access, documents product movement and maintains accountability through destruction—and how it responds when something goes wrong.
How are discrepancies and potential theft or loss investigated? What information is captured, and how are customers, carriers and regulatory authorities engaged?
3. Visibility That Turns Information Into Action
A strong reverse distribution program should provide visibility that supports better decisions—particularly when a controlled substance shipment arrives with a discrepancy or evidence of potential theft or loss.
A single compromised or missing package may appear isolated. Connecting information across incidents can reveal broader patterns.
Inmar's proprietary Rx Returns Case Management System (CMS) captures and connects controlled substance theft and loss information, including carrier, shipper, tracking information, package condition, product information, and other investigative details. The CMS documents how the supplier’s package looked when it arrived at Inmar, including photos of the outside, inside and piece-level condition of the return that can help address potential questions or claims related to diversion.
By aggregating case information, Inmar can analyze trends across factors such as carrier, customer or shipper, state, drug, location, and package condition. That additional visibility can help identify patterns, support customer and carrier engagement, and provide information for further investigation and escalation when concerns emerge.
Importantly, greater visibility can also surface losses or discrepancies that may previously have gone unidentified. The value isn't simply knowing that an exception occurred. It is having better information to understand what happened and determine what should happen next.
Visibility should do more than document the past.
It should help drive action.
4. Technology That Strengthens Compliance Rather Than Adding Complexity
Technology should create more consistent workflows, improve traceability, reduce manual intervention and provide meaningful visibility—not add complexity for the people responsible for executing the work.
At Inmar, advanced package traceability technologies—including six-sided package imaging, barcode capture, weight and dimension verification, and transaction history—create a detailed record of package movement across the returns process. Images and associated package data are securely retained for two years, providing valuable documentation to support investigations and customer inquiries.
This oversight is paramount in sensitive areas of our facilities, and our controlled substance processing and storage areas have complete camera saturation. These cameras are continuously monitored by dedicated security teams onsite and at a remote location.
Technology should make compliance easier to execute consistently while providing the traceability and documentation teams need when questions or exceptions arise.
The strongest technology investments don't simply automate processes. They strengthen the operation behind them.
5. Evidence of Continuous Evaluation and Improvement
Healthcare organizations should look beyond a partner's claims and consider how its standards and controls are evaluated as regulations, technologies and operational risks evolve.
Independent evaluation can provide one important form of validation. Inmar Rx Solutions' pharmaceutical reverse distribution operation is accredited by the National Association of Boards of Pharmacy (NABP), providing independent recognition of the standards supporting Inmar's approach to compliance, security, accountability, traceability, and operational excellence.
But continuous improvement extends beyond accreditation.
Healthcare organizations should look for evidence that a partner regularly evaluates its controls, investigates trends and exceptions, and uses what it learns to strengthen operations.
Both Inmar Rx Returns sites undergo two unannounced third-party accountability audits each year, including mock DEA inspections. Monthly security audits and third-party assessments provide additional ongoing evaluation.
Maintaining rigorous standards requires continued investment in the people, processes and technology behind the return.
Look Beyond the Return
Selecting a pharmaceutical reverse distributor should ultimately involve more than comparing how products are processed or credits are recovered.
Healthcare organizations are entrusting a partner with both regulated pharmaceutical products and an important financial component of their returns program. That requires not only rigorous standards for how products are managed, but also accurate management of complex manufacturer policies that can directly impact credit recovery.
The right reverse distribution partner should help maximize eligible credits, reduce incorrect deductions and missed recovery opportunities, and maintain the security, accountability and regulatory rigor required throughout the returns process.
That is why regulatory expertise, security and accountability, actionable visibility, technology and continuous improvement should all be part of the evaluation.
At Inmar, our Rx Returns capabilities bring these elements together through regulatory expertise, technology, operational controls, reporting, and processes designed to support compliant, secure, and efficient pharmaceutical returns—and accurate credit recovery.
Because the most important measure of a reverse distributor may not be simply what it does with a return.
It is the rigor of the operation behind it.
Learn more about how Inmar Rx Returns supports compliant, secure and accountable pharmaceutical returns.